On February 6, 2015, Dr. Nigel Rawson, Ph.D., published an article in the journal of the Canadian Health Policy Institute which speaks to the importance of patient group advocacy and support, given today’s healthcare environment in Canada. He also speaks to the shortcomings of the Canadian drug approval and review processes when it comes to funding rare disease treatments. Patient support group aHUS Canada and their efforts to secure publicly-funded access to eculizumab, the same life-saving drug approved for the treatment of PNH, are detailed in the piece.
The Canadian Association of PNH Patients provided insights to Dr. Rawson as he was putting this article together. To read the full article, please click here: http://www.canadianhealthpolicy.com/edit/files/research-pdfs/rawson–february-6–2015.pdf